Vaxcyte reports Q4 2024 net loss of $137.1M; cash $3.13B; VAX-31 Phase 3 on track for mid-2025

Vaxcyte, Inc.

2024-FY EPS reported -$3.80

Net loss Q4 2024: $137.1M; full year 2024: $463.9M vs $402.3M in 2023.
Cash, cash equivalents and investments: $3.13B at Dec 31, 2024, up from $1.24B a year ago.
R&D expenses $133.6M in Q4; $476.6M for full year on increased PCV program activities.
VAX-31 adult Phase 3 pivotal study expected to start by mid-2025 with topline data in 2026.
VAX-24 infant Phase 2 primary immunization topline data expected by end of Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.